Document Detail

Amiodarone-induced pulmonary toxicity: an under-recognized and severe adverse effect?
MedLine Citation:
PMID:  20623129     Owner:  NLM     Status:  In-Process    
Several forms of pulmonary disease occur among patients treated with amiodarone, i.e. chronic interstitial pneumonitis, organizing pneumonia, ARDS, a solitary pulmonary mass of fibrosis. The prevalence is estimated to be about 5%. Two major hypotheses of amiodarone-induced pulmonary injury include direct cytotoxicity and a hypersensitivity reaction. Given the frequency and potential severity of amiodarone-induced pulmonary toxicity, early detection is desirable. Unfortunately, there are no adequate predictors of pulmonary toxicity due to amiodarone. Patients who should benefit from amiodarone should be carefully selected and the lowest effective dosage of amiodarone should be taken. Amiodarone-induced pulmonary toxicity is a diagnosis of exclusion. Pulmonary evaluation with chest X-ray and pulmonary function testing, including diffusion capacity for carbon monoxide is recommended when amiodarone is started. A documented decline in the diffusing capacity of greater than 20% is useful in suggesting the need for closer monitoring or for further diagnostic testing. Although the optimal frequency of follow-up has not been determined, most cases of amiodarone-induced lung injury develop during the first 2 years of treatment and disease onset usually is slow. Pulmonary function tests and imaging may be performed every 3-6 months, depending on the presumed individual risk. Treatment of amiodarone pulmonary toxicity consists primarily of stopping amiodarone. Corticosteroid therapy can be life-saving for severe cases and for patients with less severe disease in whom withdrawal of amiodarone is not desirable. Due to its accumulation in fatty tissues and long elimination half-life, pulmonary toxicity may initially progress despite drug discontinuation and may recur after steroid withdrawal. The prognosis of amiodarone lung disease is generally favourable.
Martin Schwaiblmair; Thomas Berghaus; Thomas Haeckel; Theodor Wagner; Wolfgang von Scheidt
Related Documents :
19075099 - Association between c-reactive protein genotype, circulating levels, and aortic pulse w...
7302629 - Ventilation-perfusion imaging and pulmonary angiography: changing pattern of use.
25197339 - Sildenefil increases connexin 40 in smooth muscle cells through activation of bmp pathw...
1260489 - Concurrent exchange of 45ca and 3h-tetracycline from rat bone in vitro.
20623129 - Amiodarone-induced pulmonary toxicity: an under-recognized and severe adverse effect?
10735979 - Osteocalcin metabolism in the pulmonary circulation.
6334109 - Stress thallium-201 transaxial emission computed tomography: quantitative versus qualit...
10073759 - Asymptomatic carotid artery stenosis associated with peripheral vascular disease: a pro...
17300699 - Increased neuronal nitric oxide synthase interaction with soluble guanylate cyclase con...
Publication Detail:
Type:  Journal Article     Date:  2010-07-10
Journal Detail:
Title:  Clinical research in cardiology : official journal of the German Cardiac Society     Volume:  99     ISSN:  1861-0692     ISO Abbreviation:  Clin Res Cardiol     Publication Date:  2010 Nov 
Date Detail:
Created Date:  2010-10-22     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101264123     Medline TA:  Clin Res Cardiol     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  693-700     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The usefulness of laryngotracheal separation in the treatment of severe motor and intellectual disab...
Next Document:  A population-based study of selected demographic characteristics of Israeli-Jewish women with cervic...